Anti-YIPF7 monoclonal antibody

Pre-made anti-YIPF7 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to YIPF7/YIPF7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2291-Ab-1/ GM-Tg-hg-IP2291-Ab-2Anti-Human YIPF7 monoclonal antibodyHuman
GM-Tg-rg-IP2291-Ab-1/ GM-Tg-rg-IP2291-Ab-2Anti-Rat YIPF7 monoclonal antibodyRat
GM-Tg-mg-IP2291-Ab-1/ GM-Tg-mg-IP2291-Ab-2Anti-Mouse YIPF7 monoclonal antibodyMouse
GM-Tg-cynog-IP2291-Ab-1/ GM-Tg-cynog-IP2291-Ab-2Anti-Cynomolgus/ Rhesus macaque YIPF7 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2291-Ab-1/ GM-Tg-felg-IP2291-Ab-2Anti-Feline YIPF7 monoclonal antibodyFeline
GM-Tg-cang-IP2291-Ab-1/ GM-Tg-cang-IP2291-Ab-2Anti-Canine YIPF7 monoclonal antibodyCanine
GM-Tg-bovg-IP2291-Ab-1/ GM-Tg-bovg-IP2291-Ab-2Anti-Bovine YIPF7 monoclonal antibodyBovine
GM-Tg-equg-IP2291-Ab-1/ GM-Tg-equg-IP2291-Ab-2Anti-Equine YIPF7 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2291-Ab-1/ GM-Tg-hg-IP2291-Ab-2; GM-Tg-rg-IP2291-Ab-1/ GM-Tg-rg-IP2291-Ab-2;
GM-Tg-mg-IP2291-Ab-1/ GM-Tg-mg-IP2291-Ab-2; GM-Tg-cynog-IP2291-Ab-1/ GM-Tg-cynog-IP2291-Ab-2;
GM-Tg-felg-IP2291-Ab-1/ GM-Tg-felg-IP2291-Ab-2; GM-Tg-cang-IP2291-Ab-1/ GM-Tg-cang-IP2291-Ab-2;
GM-Tg-bovg-IP2291-Ab-1/ GM-Tg-bovg-IP2291-Ab-2; GM-Tg-equg-IP2291-Ab-1/ GM-Tg-equg-IP2291-Ab-2
Products NameAnti-YIPF7 monoclonal antibody
Formatmab
Target NameYIPF7
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-YIPF7 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2291-Ag-1Recombinant multi-species YIPF7/ FinGER9 protein


    Target information

    Target IDGM-IP2291
    Target NameYIPF7
    Gene ID285525,75581,364147,709996,100856581,101091108,522186,100062402
    Gene Symbol and Synonyms2310016N21Rik,FinGER9,RGD1310766,Yip1b,YIPF7
    Uniprot AccessionQ8N8F6,A5D7K7
    Uniprot Entry NameYIPF7_HUMAN,YIPF7_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000177752
    Target ClassificationN/A

    The target: YIPF7, gene name: YIPF7, also named as FinGER9. Predicted to be involved in endoplasmic reticulum to Golgi vesicle-mediated transport and vesicle fusion with Golgi apparatus. Predicted to be located in endoplasmic reticulum membrane. Predicted to be integral component of membrane. Predicted to be active in trans-Golgi network. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.